Overview

Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Status:
Unknown status

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.

Phase:

Phase 4

Details

Lead Sponsor:

Xiangbei Welman Pharmaceutical Co., Ltd

Treatments:

Piperacillin
Sulbactam